Watch our latest webinar: Who can you trust? A pharma leader’s guide to vetting AI for insights
View Now
Product manager
Our thinking
Insights, strategy, and perspectives from the Day One team
Most insight leaders can now see the strategic potential of AI. They understand where it could help them with faster sense-making, broader exploration, and decisions made with greater confidence when time is short.
In late July, Day One Strategy hosted a webinar that brought together over 100 pharmaceutical insights leads to discuss a topic at the cutting edge of market research: synthetic data and respondents. This article summarises the key takeaways from this engaging discussion, offering a window into how industry leaders are thinking about the future of data-driven insights in pharma.
In the 2013 science fiction film Her, set in the near future, a lonely writer named Theodore develops an unexpected and profound relationship with an artificially intelligent virtual assistant designed to meet his every need. Theodore is captivated by her ability to learn, adapt and exhibit human-like psychological growth. This portrayal of human-AI interaction is no longer confined to science fiction.
I’ve been working in market research for my entire career spanning a 30-year period, including leading large teams and building my own successful agency. I’m someone who is curious and open to change, so I’ve always tried to stay at the forefront of innovations, playing an active role in shaping our industry.
In the realm of artificial intelligence, two distinct teams have emerged with vastly different outlooks: the AI enthusiasts and the AI cynics. These groups represent polarized perspectives on the potential impact of generative AI.
